What is the trial?
Sponsor is developing the product RYI-018 as a potential treatment for non-alcoholic fatty liver disease (NAFLD), which is a very common disorder and refers to a group of conditions where there is accumulation of excess fat in the liver of people who drink little or no alcohol.
The purpose of this study is to evaluate the safety and tolerability of multiple doses of RYI-018 after 4 weeks of dosing in subjects with NAFLD delivered intravenously (directly into the vein).
Participants are required to attend multiple visits and overnight stays over a period of 67 days.
You are potentially eligible to participate in this trial if you –
- Are 18-65 years old
- Have BMI between 25 – 40 kg/m2
- Have been diagnosed with type 2 diabetes or pre-diabetes?
- Are willing to be screened for fatty liver disease
There are a number of other eligibility criteria that will be checked and discussed with you as part of the screening process.
Participants in this study will be remunerated for their time and inconvenience.
To find out more, please contact our friendly Recruitment team on 1300 LINEAR (1300 546 327) or email email@example.com